Myeloma comparative sequencing points to Plexxikon now, personal therapies later
This article was originally published in Scrip
Executive Summary
A multi-patient whole genome analysis study in multiple myeloma recently published in Nature which is "just the beginning" of a deeper understanding of the disease, according to its authors, has already identified an entirely new potential molecular target and given a clear signal that a drug currently showing promise in melanoma might also be effective in a significant minority of multiple myeloma patients. The publication represents the first time that multiple cancer of the same time have been comparable at the whole genome level.
You may also be interested in...
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Women In High Places: Slow Progress In Pharma
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
Stock Scan April 2018: Pharma's Fizz Falls Flat
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.